MétaCan
Menu
← Back to cohort
Record W4403833769 · doi:10.1681/asn.2024bjyvcgfe

Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

2024· article· en· W4403833769 on OpenAlexaff
Katherine R. Tuttle, Johannes F.E. Mann, Ekaterina Sokareva, Brian Rayner, Giuseppe Pugliese, Richard E. Pratley, Vlado Perkovic, Kenneth W. Mahaffey, Naoki Kashihara, Ole Kleist Jeppesen, Janusz Gumprecht, R Correa-Rotter, David Z.I. Cherney, Heidrun Bosch‐Traberg, Mustafa Kemal Arıcı, Peter Rossing

Bibliographic record

VenueJournal of the American Society of Nephrology · 2024
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsToronto General HospitalUniversity of Toronto
Fundersnot available
KeywordsSemaglutideMedicineInternal medicineKidney diseaseUrologyIntensive care medicineCardiologyEndocrinologyDiabetes mellitusType 2 diabetes

Abstract

fetched live from OpenAlex

Background: Semaglutide reduced risks of major kidney outcomes, cardiovascular (CV) events, and death from any cause in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD) in the FLOW trial. The aim of this analysis was to assess kidney outcomes by baseline CKD severity. Methods: Participants had T2D with eGFR 50–75 mL/min/1.73m2 and urine albumin–creatinine ratio (UACR) >300–<5000 mg/g, or eGFR 25–<50 mL/min/1.73m2 and UACR >100–<5000 mg/g. They were randomized to subcutaneous semaglutide 1 mg once weekly or placebo. The FLOW primary outcome was a composite of kidney failure (initiation of chronic kidney replacement therapy, eGFR <15 ml/min/1.73m2), >50% eGFR decline, or death due to kidney or CV causes. Participants were categorized by baseline eGFR and UACR. Results: Among 3533 participants, 30% (n=1069) were women. At baseline, their mean age was 67 years, mean eGFR was 47 mL/min/1.73 m2, and median UACR was 568 mg/g. The hazard ratio for the primary outcome was 0.76 (95% CI 0.66–0.88) for semaglutide versus placebo over a median of 3.4 years. Consistent results were observed across eGFR and UACR categories (Figure). Conclusion: Semaglutide safely reduced risks of major kidney outcomes irrespective of CKD severity defined by baseline eGFR or UACR in participants with T2D and CKD in the FLOW trial. Funding: Commercial Support - Novo Nordisk

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.344
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicDiabetes Treatment and Management→French-language works237,207→